Capstone Holding Corp. · NASDAQ:CAPS
Capstone — Capstone Therapeutics — Q2 2013 Earnings Presentation
14 slides from Capstone's earnings presentation, Aug 14, 2013
Slide 1: Capstone Therapeutics Operating Update
1 Capstone Therapeutics Operating Update August 14, 2013 AS CAPSTONE
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation or otherwise attributable to Capstone regarding our business that are not historical facts are forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking s
Slide 3: Cash Report
Cash Report Cash Use and Ending Balance 2Q2013 CAPS § (401,000) Lipimetix § (677,000) Consolidated § (1,078,000) Cash Balance § 8,123,000 Note: Cash Balance at June 30, 2013 includes $3.1 million held in and reserved for use by Lipimetix Development, LLC
Slide 4: Qui Tam Lawsuit Update
Qui Tam Lawsuit Update @ First discovery hearing held in February 2013 — duration of discovery process uncertain @ Proposed DOJ/Orthofix settlement accepted by court - had slowed lawsuit progress @ Settlement/Trial: Timing Unknown A CAPSTONE 4
Slide 5: LipimetiX Development LLC (JV)
LipimetiX Development LLC (JV) @ CAPS contributed $6M for 60% (ownership) @ 2 tranche funding structure @ S5M of CAPS contribution has preferential distribution right @ Lipimetix LLC (Lipi) contributed UAB license for current/future IP, for 40% (ownership) @ JV contracted Dennis Goldberg, Ph.D. and
Slide 6: AEM-28 Rational Design at UAB
AEM-28 Rational Design at UAB — 299 aa down to 28 aa with full function "Hinge region BiG Apolipoprotein E Wiis. ey Losi iets 55SD VA Vie ES CAPSTONE
Slide 7: Target Indications
Target Indications @ Homozygous Familial Hypercholesterolemia (HOFH) > Absence of LDL receptor function > Cannot clear LDL or control cholesterol levels > Orphan indication, potential for rapid development/ approval > Potential $200 million market @ Severe Refractory Hypercholesterolemia > Not respo
Slide 8: Target Indications (cont'd)
Target Indications (cont’d) @ Acute Coronary Syndrome > 1,300,000 hospitalizations/year in US alone > 10-25% recurrence rate in first year after event > Reduce atherosclerosis burden and mortality > Potential $11 Billion annual market > Will require an outcome study and funding by big Pharma
Slide 9: Homozygous FH Animal Evidence: AEM-28 Reduces LDL & VLDL
Homozygous FH Animal Evidence: AEM -28 Reduces LDL & VLDL > Watanabe Heritable Hyperlipidemic (WHHL) Rabbits have same genetic defect as human FH patients > WHHL rabbits are refractory to statins, bile acid sequestrants, etc. > Single dose of AEM-28 reduces non-HDL cholesterol 45% at 18 hours oS ‘pr
Slide 10: ACS Animal Evidence: Direct Artery Wall Effects Reduce Atherosclerosis
ACS Animal Evidence: Direct Artery Wall Effects Reduce Atherosclerosis Reduction in Atherosclerosis far Exceeds Cholesterol Drop Control Animal Plasma Cholesterol = 1600 mg/dl y fatty streaks AEM-28 Animal Plasma Cholesterol = 1100 mg/dl 08% of 1 y fatty streaks
Slide 11: Summary — Apo E Mimetics
Summary — Apo E Mimetics @ Novel mimetics of key lipid/cholesterol metabolism protein > Utilizes alternate receptors on liver to clear atherogenic lipoproteins > Induces direct anti-inflammatory and lesion regression effects on artery walls > Believed to be only product in development with both effe
Slide 12: LipimetiX Operating Update
LipimetiX Operating Update CA Joint Venture formation/Transaction completed on August 3, 2012 New AEM-28 drug material manufactured/received Pre-IND meeting letter filed with FDA Orphan Drug application approved December, 2012 by FDA for Homozygous Familial Hypercholesterolemia Preclinical Toxicity
Slide 13: Capstone Summary
Capstone Summary @ Two Programs: > Apo E Mimetic Peptide AEM-28 in LDL Reduction > AZX100 in Pulmonary Fibrosis — LRRI Results e Seeking Development Partner @ Continue CAPS Virtual Operation (1.5 Employees/ Consultants) to Preserve Cash @ Cash Resources Believed to be Adequate to Reach Value Milesto
Slide 14: Capstone Therapeutics contact details
ALS CAPSTONE THERAPEUTICS OTCQB: CAPS www.capstonethx.com Capstone Therapeutics 1275 West Washington Street — Suite 101 Tempe, AZ 85281 (602) 286-5520
Capstone Therapeutics — Q2 2013 Earnings Presentation on 6ix